Boron
Conditionally Essential Trace Mineral
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The human evidence is preliminary and small, so a 2 is honest and the current rating holds. The most cited work is Forrest H. Nielsen's USDA depletion-repletion studies from the mid-1980s: postmenopausal women moved from a low-boron diet (about 0.25 mg/day) to 3 mg/day showed roughly 44% lower urinary calcium loss and higher serum estradiol and testosterone, with effects strongest in women who were also low in magnesium (Nielsen 1987, n around 12-13). These are metabolic-balance studies in a dozen women, not fracture or density outcomes. The hormone signal in men rests on Naghii 2011, a single-arm study of eight healthy males taking 10 mg/day for one week that reported increased free testosterone and lower estradiol, SHBG, hsCRP and TNF-alpha, with no clinical endpoints. Osteoarthritis and inflammation data come from short calcium-fructoborate trials (Scorei 2011, 60 completers over two weeks; a 2016 rheumatoid arthritis adjuvant pilot of 80 patients over 60 days) reporting lower hsCRP and symptom scores, several run or supported by fructoborate-linked research groups. Against this, the one-year female-athlete trial by Meacham 1994 found no clear bone-mineral-density benefit, and the NIH Office of Dietary Supplements states boron is not classified as an essential nutrient and that supplementation did not directly affect bone mineral density in human studies. Small samples, short durations, surrogate endpoints, and industry ties keep this at preliminary/observational, not moderate-RCT.
- FDA
- Legal supplement (DSHEA); no FDA-established RDA
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Wide safety margin in healthy adults (upper limit 20 mg/day), but boron raises estradiol and testosterone in short studies, so high chronic doses warrant caution in hormone-sensitive people; the upper limit is anchored to animal reproductive toxicity, so pregnancy should stay near dietary levels (about 1-3 mg) unless a specialist advises otherwise.
Boron is a trace element found in plant foods, water, and the mineral borax, taken as a supplement in low-milligram amounts for bone, joint, and hormone support. Most Western diets supply only about 1 mg a day, below the 3-10 mg range used in the studies that report effects. The honest headline is that boron clearly changes mineral and hormone chemistry in short human studies, yet the hard outcomes people want, higher bone density and fewer fractures, are not established, and the U.S. National Institutes of Health does not classify boron as an essential nutrient. Its most reproducible human finding is that around 3 mg a day reduces urinary calcium loss and raises estradiol and testosterone in postmenopausal women, especially those low in magnesium. The testosterone-boosting and joint-relief claims that drive most sales rest on very small, short, sometimes industry-supported trials.
Conditionally essential, and most Western diets fall short of the dose range with benefit evidence.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Boron occupies an unusual position in human nutrition, formally classified as a "conditionally essential" or "probably essential" trace mineral, with substantial physiological evidence for biological roles but without the formal RDA or established essentiality status of zinc, iron, or selenium. Total body boron content is small (~20mg in a 70kg adult) but functionally significant; the mineral participates in bone matrix metabolism, calcium and magnesium handling, sex hormone modulation, and possibly cognitive function in older adults. Dietary boron intake varies enormously based on geographic soil content and food preferences, fruits (apples, raisins, grapes, prunes), nuts (almonds, hazelnuts, walnuts), legumes, and avocados are the richest food sources, while animal proteins and refined grains are poor sources. Typical Western diets provide 1-2mg/day, substantially below the 3-10mg range that clinical trials have associated with measurable physiological effects. The biological mechanisms are incompletely characterized but include enzymatic and structural roles distinct from classical essential minerals. The foundational modern boron research came from Forrest H. Nielsen at the USDA Grand Forks Human Nutrition Research Center in the 1980s-1990s. Nielsen's seminal 1987 FASEB Journal paper demonstrated that boron supplementation (3mg/day) in postmenopausal women on low-boron diets produced substantial reductions in urinary calcium and magnesium loss, with elevations in plasma 17β-estradiol and ionized calcium. This work established the modern boron-bone-hormonal framework that has guided subsequent research. The mechanism involves multiple pathways: boron influences calcium and magnesium retention through unclear renal effects; boron modulates vitamin D metabolism (with vitamin D status affecting boron requirements); boron affects sex steroid metabolism by mechanisms that may involve estrogen and testosterone receptor modulation or steroidogenic enzyme effects; boron may influence inflammation markers and oxidative stress in joint tissue. The hormone modulation is particularly intriguing, supplemental boron at 3-10mg/day produces measurable increases in plasma estradiol (relevant for postmenopausal bone health context) and testosterone (relevant for men's health applications, though clinical significance debated). The mineral category position is unusual: not classical essential mineral, not true micronutrient like vitamins, but with persistent metabolic effects suggesting conditional essentiality at doses above typical Western dietary intake.
How it is taken
Standard boron supplementation centers on 3-10mg/day elemental boron, the range across most clinical trials including Nielsen 1987 postmenopausal bone work, Travers 1990 osteoarthritis observations, Penland 1994 cognitive evidence, and Naghii 2011 hormonal trials. The lower end (3mg/day) approaches dietary levels achievable through boron-rich food choices; the upper end (10mg/day) is the typical therapeutic supplementation level. Take with food, boron absorption is acceptable but may be slightly better with food. Take with calcium and magnesium for synergistic bone effects (mechanistically integrated through calcium and magnesium handling). The Upper Limit (UL) is 20mg/day for adults per IOM 2001, based primarily on reproductive toxicity concerns from occupational exposure data and limited supplementation evidence at very high doses. Most users should stay below 10mg/day without specific clinical indication. The vaginal boric acid antifungal protocol (600mg vaginal capsule daily for 14 days) is a separate specialty topical use case, not oral supplementation. The therapeutic window is relatively broad in healthy adults but the lack of widely-accepted boron status marker makes individual targeting difficult, typical guidance is to ensure dietary or modest supplemental intake in the 3-10mg/day range rather than precise individual titration. Long-term safety at typical supplementation doses is good across decades of Nielsen group research and other long-term work. The geographic variation in dietary boron (high in volcanic-soil areas like Israel, Jamaica, Mauritius; low in much of glaciated North America and Europe) supports population-level boron status variation that may make supplementation more or less important based on residence.
- Typical Western dietary intake
- 1-2mg/day
- Boron-rich diet intake
- 3-5mg/day
- Therapeutic supplementation range
- 3-10mg/day
- Nielsen 1987 postmenopausal
- 3mg/day
- Naghii 2011 testosterone trial
- 10mg/day
- Osteoarthritis (Travers tradition)
- 6-9mg/day
- IOM Upper Limit (UL) adults
- 20mg/day
- Adolescent UL
- 17mg/day
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Boron Glycinate (Chelate)
Amino acid chelate form with excellent bioavailability and tolerability. Albion/Balchem patented chelation chemistry produces stable bioavailable form. Reasonable choice for therapeutic supplementation. Premium pricing relative to non-chelated forms but generally justified.
Boron Citrate
Citrate form with good bioavailability and reasonable cost. Common in joint health and bone density formulations. Acceptable for most therapeutic applications.
Boron Aspartate
Aspartic acid chelate. Reasonable absorption profile; common in bone health formulations. Acceptable alternative to other chelated forms.
Sodium Borate (Borax)
Inorganic borate salt, the original "borax" of household products. Higher elemental boron content (~11% by weight) but less acceptable for oral therapeutic use given inorganic chemistry. Some traditional and alternative medicine protocols use borax, substantial controversy about safety and appropriate dosing. Consumer-grade household borax is NOT pharmaceutical grade. Reasonable caution about this form.
Boric Acid
Inorganic boron form used in antifungal vaginal suppositories (recurrent vulvovaginal candidiasis treatment) and other specialty applications. Pharmaceutical-grade in specific clinical contexts; not consumer oral supplement form. Limited oral therapeutic use case outside specific clinical indications.
Whole Food Boron (Fruits, Nuts, Legumes)
Dietary boron from apples, raisins, prunes, grapes, almonds, hazelnuts, walnuts, avocados, legumes. Typical Western diet provides 1-2mg/day from these sources; diets rich in these foods can provide 3-5mg/day approaching therapeutic levels without supplementation. Most reliable foundation for boron status.
Combined Bone Health Formulations
Boron commonly included in comprehensive bone health products alongside calcium, magnesium, vitamin D3, vitamin K2, and other bone cofactors. Mechanistically reasonable for users seeking comprehensive bone support; verify boron dose specifically rather than relying on category positioning. Solgar, Now Foods, Thorne, and other major manufacturers offer reliable combinations.
Low-Dose Multivitamin Boron
Most multivitamins include boron at modest doses (0.5-2mg). Contributes to dietary intake without exceeding therapeutic levels. Reasonable foundation; targeted higher-dose supplementation for specific indications.
Who it works for, and who it does not
Postmenopausal bone health (Nielsen foundation)
Nielsen 1987 foundational evidence and subsequent work support boron at 3-10mg/day for postmenopausal women on low-boron diets, reducing urinary calcium loss, supporting hormone status, and contributing to comprehensive bone health. Effect sizes modest; reasonable adjunct to calcium, vitamin D3, K2, and exercise. Not substitute for bisphosphonates or other established osteoporosis treatment in severe disease.
Osteoarthritis joint comfort
Travers 1990 observational evidence and subsequent preliminary work support boron at 6-9mg/day for joint comfort in osteoarthritis. Effect sizes preliminary; reasonable adjunct to glucosamine, chondroitin, and other joint health interventions. Not substitute for established arthritis management in severe disease.
Men with low testosterone (preliminary)
Naghii 2011 and similar trials show acute testosterone increases with high-dose boron (10mg/day) in healthy men. Whether modest hormonal shifts produce clinically meaningful outcomes for men with diagnosed low testosterone remains preliminary. Coordinate with endocrinology for established hypogonadism; not substitute for established testosterone therapy.
Vitamin D metabolism support
Boron supports vitamin D activation and reduces urinary calcium loss, mechanistically complementary to vitamin D supplementation. Reasonable adjunct in comprehensive bone and calcium nutrition. Particular relevance for users with vitamin D supplementation programs.
Cognitive function in older adults
Penland 1994 and preliminary subsequent work suggest cognitive function differences between low-boron and adequate-boron states in older adults. Mechanism poorly characterized; effect sizes preliminary. Reasonable component of comprehensive cognitive nutrition; not standalone cognitive intervention.
Healthy adults (general supplementation)
Reasonable component of comprehensive nutrition for healthy adults, particularly given typical Western intake substantially below clinical trial doses. Effect sizes modest in healthy non-deficient users; clear individual identification of boron-deficient users is challenging given no widely-accepted boron status marker.
Vulvovaginal candidiasis (recurrent)
Boric acid vaginal suppositories (600mg vaginal capsule daily for 14 days) are established second-line therapy for recurrent vulvovaginal candidiasis, particularly non-albicans species (Candida glabrata). Specialist coordination through women's health. This is topical boric acid pharmaceutical use, distinct from oral supplementation.
Pregnancy and lactation
Limited systematic safety data for high-dose boron supplementation in pregnancy. Reproductive toxicity has been demonstrated in animals at high doses (occupational exposure relevance). Stick to dietary levels (1-3mg) absent specialist guidance; routine therapeutic supplementation in pregnancy not recommended.
Pediatric use
Limited safety data in pediatric populations. UL is lower in adolescents (17mg/day) and younger children (3-11mg/day depending on age). Routine pediatric supplementation outside specific clinical indication not warranted.
Hormone-sensitive cancers
The mild estradiol-increasing effect of high-dose boron warrants caution in users with hormone-sensitive cancers (breast, ovarian, endometrial). Specialist coordination through oncology. Mainstream evidence is preliminary but caution is reasonable.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Calcium
Boron supports calcium retention and reduces urinary calcium loss. Common combination in bone health protocols. Mechanistically integrated through calcium handling pathways.
Magnesium
Similar synergy through magnesium retention support. Common combination in comprehensive bone and joint formulations.
Vitamin D3
Boron supports vitamin D metabolism and reduces urinary calcium loss complementary to vitamin D-mediated calcium absorption. Mechanistically integrated bone protocol.
Vitamin K2
Comprehensive bone protocol, boron + calcium + magnesium + D3 + K2 represents the modern comprehensive bone supplementation approach. Each component addresses different aspects of calcium handling and bone matrix formation.
Glucosamine and Chondroitin
Common joint health combination. Boron contributes through possibly distinct mechanisms (joint matrix support, anti-inflammatory effects); glucosamine and chondroitin provide cartilage substrate support.
Hormone-Sensitive Cancers (Caution)
Mild estradiol-increasing effect of high-dose boron warrants caution in users with hormone-sensitive cancers. Coordinate with oncology before high-dose supplementation.
Estrogenic Medications and Hormone Therapy
Boron's hormonal effects may interact with hormone replacement therapy or other hormonal medications. Coordinate with prescribing physician for users on hormonal therapy.
Riboflavin (Vitamin B2)
Some emerging research suggests boron-riboflavin interaction in cognitive function. Mechanistically preliminary; common in B-complex multivitamins anyway.
Phytoestrogens
Combined effects with isoflavones and other phytoestrogens may produce additive mild estrogenic effects. Reasonable consideration for postmenopausal women using both; specialist coordination for hormone-sensitive contexts.
What to look for on the label
Look for: specific boron compound form disclosed (citrate, glycinate, aspartate); explicit elemental boron content (not just compound weight); appropriate dose for indication (3-10mg elemental boron); USP or NSF third-party verification; reputable manufacturer with quality control disclosure; reasonable price. Avoid: products without elemental boron disclosure; proprietary "bone health" blends obscuring boron dose; products marketed with very high-dose claims (>20mg/day chronic) without specific indication; household borax for oral use (substantial safety concern); products from manufacturers without third-party testing disclosure.
Safety in detail
- Generally well-tolerated at supplementation doses (3-10mg/day). The Upper Limit (UL) of 20mg/day reflects reproductive toxicity concerns from occupational exposure data rather than typical supplementation toxicity.
- Acute supplementation toxicity is uncommon, boron has a relatively broad therapeutic window in adult humans compared to many minerals.
- Reproductive toxicity has been demonstrated in animals at very high doses (occupational and industrial exposure relevance). Stick to UL <20mg/day in adults; lower in women of reproductive age.
- Pregnancy: standard prenatal vitamins do not include therapeutic-level boron; stick to dietary levels (1-3mg) in pregnancy absent specialist guidance.
- Pediatric use: UL is lower in adolescents and children; routine pediatric supplementation outside specific clinical indication not warranted.
- GI upset is uncommon at supplementation doses; high doses may produce mild nausea or abdominal discomfort.
- Mild estradiol-increasing effect at high doses (10mg/day) warrants caution in hormone-sensitive cancer survivors.
- Borax (household sodium borate) toxicity is documented in industrial and accidental exposure contexts; this is separate from pharmaceutical-grade boron supplements at typical doses. The "borax for health" alternative medicine practice carries safety concerns and is not equivalent to pharmaceutical-grade boron supplementation.
- Vaginal boric acid antifungal protocol has established safety in adult women under specialist guidance; not appropriate for pregnancy or pediatric use.
- Long-term safety record at typical supplementation doses is good across decades of Nielsen group and other research; no major adverse signal documented at typical supplementation levels.
What people get wrong
Often saidBoron is essential like iron or zinc.
ActuallyFormally, boron is classified as "potentially essential" or "conditionally essential" rather than essential like classical essential minerals. The evidence base is substantial but without the unambiguous deficiency syndromes characterizing true essential minerals.
Often saidBoron is a testosterone booster.
ActuallyHigh-dose boron (10mg/day) produces modest acute testosterone increases in healthy men per Naghii 2011 and similar work. The clinical translation for men with diagnosed low testosterone is preliminary; effect sizes are modest. Reasonable adjunct in men's health nutrition; not substitute for established testosterone evaluation.
Often saidBorax for health is the same as boron supplements.
ActuallyIt is not. Pharmaceutical-grade boron supplements use purified boron compounds (citrate, glycinate, aspartate) at appropriate therapeutic doses. Household borax is industrial sodium borate; the "borax for health" alternative medicine practice circulating online carries safety concerns and is not equivalent to proper supplementation.
Often saidHigher boron doses always produce better results.
ActuallyDiminishing returns set in above 10mg/day. The IOM Upper Limit of 20mg/day reflects safety concerns at high chronic intake. Most clinical evidence clusters at 3-10mg/day.
Often saidBoron has no drug interactions.
ActuallyMild estradiol-increasing effect warrants caution in hormone-sensitive cancers. Interactions with hormone replacement therapy and other hormonal medications. Specialist coordination for hormone-related contexts.
Often saidYou can't get enough boron from food.
ActuallyYou can, diets rich in fruits (apples, raisins, prunes), nuts (almonds, hazelnuts, walnuts), legumes, and avocados can provide 3-5mg/day approaching therapeutic levels. The "everyone needs boron supplements" framing exceeds the evidence; targeted supplementation is reasonable in users with diets low in these foods.
Often saidBoron is dangerous because borax is toxic.
ActuallyBorax (household sodium borate) toxicity in industrial and accidental exposure contexts is distinct from properly-formulated boron supplements at typical doses. Pharmaceutical-grade boron supplements at 3-10mg/day have good safety profiles across decades of research.
Who profits, and who pushes back
Mainstream nutritional science (formal essentiality skepticism)
Despite accumulating evidence over four decades, boron has not gained formal essential mineral status from IOM or mainstream nutritional science bodies. The "potentially essential" or "conditionally essential" classification reflects evidence base position, substantial physiological evidence but without the unambiguous deficiency syndrome and clinical consequences that characterize true essential minerals (iron-deficiency anemia, iodine-deficiency goiter, zinc-deficiency growth failure). Boron warrants attention as significant supplementation candidate; consumer marketing should acknowledge the formal essentiality ambiguity rather than presenting boron as classical essential nutrient.
Hormonal effects clinical relevance assessment
The Naghii 2011 testosterone trial and similar work show modest acute hormonal effects with high-dose boron (10mg/day) in healthy men. Whether these modest hormonal shifts translate to clinically meaningful outcomes for men with diagnosed low testosterone remains preliminary. Consumer marketing of boron as "testosterone booster" frequently exceeds the actual evidence base, the effect sizes are modest, the populations studied limited, and the clinical translation uncertain. Reasonable use as part of comprehensive men's health nutrition; not substitute for established low testosterone evaluation and treatment.
Forrest H. Nielsen
Foundational figure in modern human boron research. Conducted FASEB 1987 postmenopausal trial and decades of subsequent boron physiology work at USDA Grand Forks Human Nutrition Research Center. Independent government academic; foundational scientific contribution.
Curtiss Hunt
Nielsen group colleague who conducted detailed boron-calcium-magnesium metabolism mechanism research. Independent government academic.
Rex Newnham
Australian researcher who conducted extensive observational work connecting geographic boron-soil variation with arthritis prevalence. Substantial preliminary evidence for boron-joint health framework. Independent researcher.
Joseph Pizzorno
Lead author of 2015 comprehensive boron review consolidating multi-decade evidence base. Integrative medicine practitioner and educator with significant influence on functional medicine adoption of boron.
James Penland
Nielsen group colleague who conducted 1994 cognitive function trial. Independent government academic.
Eti Maden (Turkey)
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Turkish state-owned mining company controlling approximately 70% of global boron supply. Substantial commercial interest in boron supply chain and applications. Industrial supplier rather than supplement advocate but commercially relevant.
Albion/Balchem
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Patent holder for specific boron glycinate chelation chemistry. Substantial commercial interest in premium boron supplement category. Disclosed industry source for chelated boron product research.
Where the research comes from
| Place | Share of published research |
|---|---|
| North America | 42% |
| Europe | 28% |
| Asia | 18% |
| Other | 12% |
Research published from: France · UK.
How we got here
Boron's discovery as a chemical element came in 1808 through essentially simultaneous isolation by Joseph Louis Gay-Lussac and Louis Jacques Thénard in France, and independently by Sir Humphry Davy in England. The element was named from the Arabic "buraq" (the Arabic name for borax) through medieval and early modern European usage. Borax (sodium borate) had been known and used in metallurgy, glass-making, and medicine for centuries before elemental boron was characterized, Marco Polo reportedly brought borax samples from Tibet to Europe in the 13th century, contributing to European chemical knowledge. The nutritional era for boron emerged remarkably late in modern nutritional science. Boron's essentiality in plants was established in 1923 through Warington's tomato cultivation experiments, plants without boron failed to thrive, establishing boron as essential plant micronutrient. The animal nutrition evidence developed through the 20th century with various experimental observations, but boron essentiality in human nutrition remained ambiguous through most of the 20th century. The Institute of Medicine has historically classified boron as "potentially essential" rather than formally essential. The modern human boron evidence base developed substantially through Forrest H. Nielsen's work at the USDA Grand Forks Human Nutrition Research Center in the 1980s-1990s. Nielsen's 1987 FASEB Journal paper demonstrating boron effects on postmenopausal calcium handling and hormonal markers became foundational evidence for the modern bone health and hormonal modulation framework. Subsequent Nielsen group work characterized cognitive effects (Penland 1994), calcium and magnesium metabolism (Hunt 1994), and various other applications through the 1990s. The geographic boron variation evidence developed through Rex Newnham's observational work in the 1990s, connecting high-boron-soil populations (Mauritius, Jamaica, Israel) with lower arthritis prevalence than low-boron-soil populations. Travers 1990 Australian observational evidence extended this with interventional implications. The vaginal boric acid antifungal application emerged from clinical observation that boric acid had antifungal activity, particularly against non-albicans Candida species. CDC guidelines and women's health practice incorporated boric acid as second-line therapy for recurrent vulvovaginal candidiasis through the 2010s-2020s. The modern consumer market era expanded substantially through the 2000s-2010s with boron becoming common in bone health and men's health supplements. The Naghii 2011 testosterone work contributed to substantial men's health marketing of boron, sometimes exceeding the clinical evidence base. The IOM 2001 Upper Limit (UL) of 20mg/day for adults established the safety framework that has informed regulatory guidance globally. The 2010s-2020s have seen substantial functional medicine and integrative practice incorporation of boron in comprehensive nutrition protocols, particularly for postmenopausal bone health, men's health, and joint comfort applications. Mainstream nutritional guidance remains more cautious about formal essentiality status. The "borax for health" alternative medicine practice has emerged as a separate (and concerning) phenomenon, internet circulation of high-dose borax protocols carries safety concerns and is not equivalent to pharmaceutical-grade boron supplementation.
- 1808Gay-Lussac, Thénard (France) and Davy (UK) isolate elemental boron
- 1923Warington establishes boron essentiality in plants
- 1980sNielsen begins USDA Grand Forks human boron research program
- 1987Nielsen FASEB Journal postmenopausal bone trial
- 1990Travers Australian osteoarthritis observational evidence
- 1991-1994Newnham geographic boron-arthritis prevalence work
- 1994Penland cognitive function trial; Hunt bone metabolism mechanism
- 2001IOM establishes UL at 20mg/day for adults
- 2010sVaginal boric acid antifungal protocol adoption (recurrent VVC)
- 2011Naghii testosterone trial in healthy men
- 2015Pizzorno comprehensive systematic review
- 2010s-2020sFunctional medicine integration; men's health marketing expansion
What we do not know
- Whether boron will gain formal essential mineral status given accumulating physiological evidence, current "conditionally essential" classification reflects evidence base position.
- Whether widely-accepted boron status markers will emerge, current research uses dietary records or experimental low-boron diets rather than validated clinical markers.
- Whether the hormonal effects (estradiol, testosterone increases) translate to clinically meaningful outcomes in specific populations beyond modest effect sizes documented.
- Whether boron has specific cognitive applications in mild cognitive impairment or age-related cognitive decline beyond the Penland 1994 preliminary evidence.
- Whether geographic boron variation should inform population-level supplementation strategies, current guidance is largely indifferent to residence.
- Whether the osteoarthritis evidence will mature beyond Travers 1990 observational work into rigorous interventional trials at scale.
- Whether the mild estradiol-increasing effect at high doses produces meaningful hormone-sensitive cancer risk at long-term supplementation levels.
- Whether the vaginal boric acid antifungal indication will extend to other clinical applications or remain specific to recurrent VVC.
Legal status
Widely available globally as dietary supplement and food ingredient. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list. Pharmaceutical applications: vaginal boric acid suppositories are available by prescription for recurrent vulvovaginal candidiasis treatment. Major retail brands include Solgar (Boron Citrate), NOW Foods (multiple forms), Thorne (Boron Glycinate), Pure Encapsulations, Designs for Health, Source Naturals, and most multivitamin and bone health product manufacturers. Production is concentrated in Turkey (largest global boron producer), United States (California Trona deposits), and select other locations. Quality variation across brands is modest given the well-established mineral chemistry; third-party testing (USP, NSF) provides standard verification. The Albion/Balchem chelated boron forms (boron glycinate) carry patent protection but generic chelated forms from other manufacturers provide equivalent function. Pricing has remained reasonable at supplement scale across global markets.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Boron sourcing originates from boron mineral deposits, particularly borax (sodium borate) and colemanite ore. Turkey is the dominant global producer (approximately 70% of global boron supply from Eti Maden operations); United States (Rio Tinto Boron operations in California) is the second-largest. Chile, Argentina, China, and Russia also produce boron. Supplement-grade boron compounds are produced from purified boron minerals through controlled chemical processing, boron citrate, boron aspartate, boron glycinate (Albion/Balchem chelation chemistry), and other forms. Quality variation across brands is modest given the well-established chemistry. Third-party testing (USP, NSF) provides standard verification. The Albion/Balchem chelated forms carry quality consistency that may justify modest premium pricing for premium brands; generic chelated forms from reputable manufacturers provide equivalent function. Borax household products are NOT pharmaceutical grade and should not be used for therapeutic oral supplementation, this is a substantial consumer safety concern given internet circulation of "borax for health" protocols.
At a glance
- Class
- Conditionally essential / potentially essential trace mineral
- Element discovery
- 1808 (Gay-Lussac, Thénard, Davy)
- Plant essentiality establishment
- 1923 (Warington)
- Modern human evidence foundation
- Nielsen 1987 (FASEB Journal)
- Typical Western dietary intake
- 1-2mg/day
- Boron-rich diet potential
- 3-5mg/day
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Boron. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Comprehensive review of boron's roles in bone, calcium/magnesium metabolism, vitamin D, inflammation, cognition, and the 3 mg/day threshold for benefit; upper limit 20 mg/day.
Pizzorno L, 'Nothing Boring About Boron,' Integrative Medicine (Encinitas), 2015; NIH PMC
In 8 healthy men, one week of 10 mg/day boron increased free testosterone and decreased estradiol, SHBG, hsCRP and TNF-alpha; first human report, no clinical endpoints.
NIH official position: boron not classified as an essential nutrient, no RDA/AI/EAR, tolerable upper intake 20 mg/day for adults, human supplementation did not directly affect bone mineral density, UL based on animal reproductive/developmental toxicity.
NIH Office of Dietary Supplements, Boron Health Professional Fact Sheet
Calcium fructoborate delivering 1.5-6 mg boron/day over two weeks reduced hsCRP and fibrinogen versus placebo in primary osteoarthritis; 60 completers; supported by Natural Research Ltd (Romania).
One-year boron supplementation in female athletes and sedentary women affected serum phosphorus, magnesium, and urinary boron but showed no clear bone-mineral-density benefit.
Consumer summary that most U.S. adults get about 1 mg boron/day, that boron is not established as essential, and list of main food sources including prune juice, coffee, milk, apples, beans.
NIH Office of Dietary Supplements, Boron Consumer Fact Sheet
Adjuvant calcium fructoborate and borax (about 6 mg boron/day) with etanercept over 60 days in rheumatoid arthritis patients; small randomized pilot reporting symptom and inflammatory changes.
Proposed mechanism that boron up-regulates vitamin D function by inhibiting 24-hydroxylase, slowing vitamin D catabolism (hypothesis paper).
Borax was first found in dry lake beds in Tibet, and native tincal from Tibet, Persia, and other parts of Asia was traded via the Silk Road to the Arabian Peninsula in the 8th century AD.
World Health Organization Environmental Health Criteria assessment of boron, source for the acceptable safe range of boron intakes for adults of about 1-13 mg/day cited by NIH ODS.
WHO, Environmental Health Criteria 204: Boron (IRIS repository)
The studies that matter
Nielsen FASEB Journal postmenopausal trialFASEB J 1987
Forrest H. Nielsen at USDA Grand Forks Human Nutrition Research Center: 3mg/day boron in postmenopausal women on low-boron diet substantially reduced urinary calcium loss and increased plasma 17β-estradiol and ionized calcium. Foundational modern boron evidence that established the bone-hormonal framework.
Nielsen comprehensive reviewJ Trace Elem Exp Med 1994
Comprehensive Nielsen review consolidating accumulating boron evidence across bone metabolism, hormonal modulation, cognitive function, and other applications. Foundational review establishing the conditional essentiality framework.
Penland cognitive function elderlyEnviron Health Perspect 1994
Nielsen group trial: low-boron diet (0.25mg/day) versus boron supplementation (3.25mg/day) in older adults produced differences in cognitive function and motor performance. Foundational cognitive boron evidence; mechanism poorly characterized but reproducible.
Travers boron osteoarthritisJ Nutr Med 1990
Australian observational study connecting boron-rich diet (and supplemental boron at 6-9mg/day) with reduced osteoarthritis prevalence in Australian populations. Foundational osteoarthritis evidence; preliminary but methodologically interesting.
Newnham boron geographic prevalenceMagnes Trace Elem 1991-1994
Rex Newnham's observational work connecting geographic boron variation with arthritis prevalence, Mauritius, Jamaica, Israel high-boron-soil populations showed lower arthritis rates than low-boron-soil populations. Foundational geographic evidence preceding interventional trials.
Naghii multiple endpoints male trialInt J Vitam Nutr Res 2011
Iranian trial: 10mg/day boron in healthy men for one week produced increases in plasma free testosterone, decrease in estradiol, and decreased inflammatory markers. Foundational acute hormonal evidence in men.
Pizzorno boron systematic reviewIntegr Med (Encinitas) 2015
Comprehensive review of boron physiological effects consolidating multi-decade evidence base across bone, hormonal, cognitive, and joint applications. Foundational integrative medicine review.
Hunt boron bone metabolismEnviron Health Perspect 1994
Hunt and Nielsen at USDA Grand Forks: detailed work on boron effects on calcium and magnesium metabolism, vitamin D interactions, and bone-specific markers. Foundational bone metabolism mechanism characterization.
Penland multi-endpoint trialEnviron Health Perspect 1994
Multi-endpoint Nielsen group trial demonstrating boron supplementation effects on calcium and magnesium retention, hormonal markers, and other endpoints. Methodological foundation for subsequent boron research.
IOM safety reviewInstitute of Medicine 2001
Institute of Medicine review establishing Upper Limit (UL) at 20mg/day for adults, 17mg/day for adolescents, lower for younger pediatric populations. Foundational safety framework that has informed regulatory guidance globally.